PandemieGrippaleV1, PubMed, Checkpoint, bibRecord, 000A09

H5N1 vaccines in humans.

Identifieur interne : 000A09 ( PubMed/Checkpoint ); précédent : 000A08; suivant : 000A10

H5N1 vaccines in humans.

Auteurs : Mariana Baz [États-Unis] ; Catherine J. Luke ; Xing Cheng ; Hong Jin ; Kanta Subbarao

Source :

Virus research [ 1872-7492 ] ; 2013.

RBID : pubmed:23726847

Descripteurs français

KwdFr :
- Animaux, Anticorps antiviraux (immunologie), Grippe humaine (), Grippe humaine (immunologie), Grippe humaine (virologie), Humains, Sous-type H5N1 du virus de la grippe A (génétique), Sous-type H5N1 du virus de la grippe A (immunologie), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (génétique), Vaccins antigrippaux (immunologie).
MESH :
- administration et posologie : Vaccins antigrippaux.
- génétique : Sous-type H5N1 du virus de la grippe A, Vaccins antigrippaux.
- immunologie : Anticorps antiviraux, Grippe humaine, Sous-type H5N1 du virus de la grippe A, Vaccins antigrippaux.
- virologie : Grippe humaine.
- Animaux, Grippe humaine, Humains.

English descriptors

KwdEn :
- Animals, Antibodies, Viral (immunology), Humans, Influenza A Virus, H5N1 Subtype (genetics), Influenza A Virus, H5N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (genetics), Influenza Vaccines (immunology), Influenza, Human (immunology), Influenza, Human (prevention & control), Influenza, Human (virology).
MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , genetics : Influenza Vaccines.
- chemical , immunology : Antibodies, Viral, Influenza Vaccines.
- genetics : Influenza A Virus, H5N1 Subtype.
- immunology : Influenza A Virus, H5N1 Subtype, Influenza, Human.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Animals, Humans.

Abstract

The spread of highly pathogenic avian H5N1 influenza viruses since 1997 and their virulence for poultry and humans has raised concerns about their potential to cause an influenza pandemic. Vaccines offer the most viable means to combat a pandemic threat. However, it will be a challenge to produce, distribute and implement a new vaccine if a pandemic spreads rapidly. Therefore, efforts are being undertaken to develop pandemic vaccines that use less antigen and induce cross-protective and long-lasting responses, that can be administered as soon as a pandemic is declared or possibly even before, in order to prime the population and allow for a rapid and protective antibody response. In the last few years, several vaccine manufacturers have developed candidate pandemic and pre-pandemic vaccines, based on reverse genetics and have improved the immunogenicity by formulating these vaccines with different adjuvants. Some of the important and consistent observations from clinical studies with H5N1 vaccines are as follows: two doses of inactivated vaccine are generally necessary to elicit the level of immunity required to meet licensure criteria, less antigen can be used if an oil-in-water adjuvant is included, in general antibody titers decline rapidly but can be boosted with additional doses of vaccine and if high titers of antibody are elicited, cross-reactivity against other clades is observed. Prime-boost strategies elicit a more robust immune response. In this review, we discuss data from clinical trials with a variety of H5N1 influenza vaccines. We also describe studies conducted in animal models to explore the possibility of reassortment between pandemic live attenuated vaccine candidates and seasonal influenza viruses, since this is an important consideration for the use of live vaccines in a pandemic setting.

DOI: 10.1016/j.virusres.2013.05.006
PubMed: 23726847

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000A14
to stream PubMed, to step Curation: 000A14

Links to Exploration step

pubmed:23726847

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">H5N1 vaccines in humans.</title>
<author><name sortKey="Baz, Mariana" sort="Baz, Mariana" uniqKey="Baz M" first="Mariana" last="Baz">Mariana Baz</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Luke, Catherine J" sort="Luke, Catherine J" uniqKey="Luke C" first="Catherine J" last="Luke">Catherine J. Luke</name>
</author>
<author><name sortKey="Cheng, Xing" sort="Cheng, Xing" uniqKey="Cheng X" first="Xing" last="Cheng">Xing Cheng</name>
</author>
<author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23726847</idno>
<idno type="pmid">23726847</idno>
<idno type="doi">10.1016/j.virusres.2013.05.006</idno>
<idno type="wicri:Area/PubMed/Corpus">000A14</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A14</idno>
<idno type="wicri:Area/PubMed/Curation">000A14</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A14</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000A09</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A09</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">H5N1 vaccines in humans.</title>
<author><name sortKey="Baz, Mariana" sort="Baz, Mariana" uniqKey="Baz M" first="Mariana" last="Baz">Mariana Baz</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Luke, Catherine J" sort="Luke, Catherine J" uniqKey="Luke C" first="Catherine J" last="Luke">Catherine J. Luke</name>
</author>
<author><name sortKey="Cheng, Xing" sort="Cheng, Xing" uniqKey="Cheng X" first="Xing" last="Cheng">Xing Cheng</name>
</author>
<author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
</author>
</analytic>
<series><title level="j">Virus research</title>
<idno type="eISSN">1872-7492</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Viral (immunology)</term>
<term>Humans</term>
<term>Influenza A Virus, H5N1 Subtype (genetics)</term>
<term>Influenza A Virus, H5N1 Subtype (immunology)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (genetics)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (immunology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (immunologie)</term>
<term>Grippe humaine (virologie)</term>
<term>Humains</term>
<term>Sous-type H5N1 du virus de la grippe A (génétique)</term>
<term>Sous-type H5N1 du virus de la grippe A (immunologie)</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (génétique)</term>
<term>Vaccins antigrippaux (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Sous-type H5N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Grippe humaine</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Grippe humaine</term>
<term>Humains</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The spread of highly pathogenic avian H5N1 influenza viruses since 1997 and their virulence for poultry and humans has raised concerns about their potential to cause an influenza pandemic. Vaccines offer the most viable means to combat a pandemic threat. However, it will be a challenge to produce, distribute and implement a new vaccine if a pandemic spreads rapidly. Therefore, efforts are being undertaken to develop pandemic vaccines that use less antigen and induce cross-protective and long-lasting responses, that can be administered as soon as a pandemic is declared or possibly even before, in order to prime the population and allow for a rapid and protective antibody response. In the last few years, several vaccine manufacturers have developed candidate pandemic and pre-pandemic vaccines, based on reverse genetics and have improved the immunogenicity by formulating these vaccines with different adjuvants. Some of the important and consistent observations from clinical studies with H5N1 vaccines are as follows: two doses of inactivated vaccine are generally necessary to elicit the level of immunity required to meet licensure criteria, less antigen can be used if an oil-in-water adjuvant is included, in general antibody titers decline rapidly but can be boosted with additional doses of vaccine and if high titers of antibody are elicited, cross-reactivity against other clades is observed. Prime-boost strategies elicit a more robust immune response. In this review, we discuss data from clinical trials with a variety of H5N1 influenza vaccines. We also describe studies conducted in animal models to explore the possibility of reassortment between pandemic live attenuated vaccine candidates and seasonal influenza viruses, since this is an important consideration for the use of live vaccines in a pandemic setting. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23726847</PMID>
<DateCompleted><Year>2014</Year>
<Month>06</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>12</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7492</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>178</Volume>
<Issue>1</Issue>
<PubDate><Year>2013</Year>
<Month>Dec</Month>
<Day>05</Day>
</PubDate>
</JournalIssue>
<Title>Virus research</Title>
<ISOAbbreviation>Virus Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>H5N1 vaccines in humans.</ArticleTitle>
<Pagination><MedlinePgn>78-98</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virusres.2013.05.006</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0168-1702(13)00171-8</ELocationID>
<Abstract><AbstractText>The spread of highly pathogenic avian H5N1 influenza viruses since 1997 and their virulence for poultry and humans has raised concerns about their potential to cause an influenza pandemic. Vaccines offer the most viable means to combat a pandemic threat. However, it will be a challenge to produce, distribute and implement a new vaccine if a pandemic spreads rapidly. Therefore, efforts are being undertaken to develop pandemic vaccines that use less antigen and induce cross-protective and long-lasting responses, that can be administered as soon as a pandemic is declared or possibly even before, in order to prime the population and allow for a rapid and protective antibody response. In the last few years, several vaccine manufacturers have developed candidate pandemic and pre-pandemic vaccines, based on reverse genetics and have improved the immunogenicity by formulating these vaccines with different adjuvants. Some of the important and consistent observations from clinical studies with H5N1 vaccines are as follows: two doses of inactivated vaccine are generally necessary to elicit the level of immunity required to meet licensure criteria, less antigen can be used if an oil-in-water adjuvant is included, in general antibody titers decline rapidly but can be boosted with additional doses of vaccine and if high titers of antibody are elicited, cross-reactivity against other clades is observed. Prime-boost strategies elicit a more robust immune response. In this review, we discuss data from clinical trials with a variety of H5N1 influenza vaccines. We also describe studies conducted in animal models to explore the possibility of reassortment between pandemic live attenuated vaccine candidates and seasonal influenza viruses, since this is an important consideration for the use of live vaccines in a pandemic setting. </AbstractText>
<CopyrightInformation>Published by Elsevier B.V.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baz</LastName>
<ForeName>Mariana</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Luke</LastName>
<ForeName>Catherine J</ForeName>
<Initials>CJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cheng</LastName>
<ForeName>Xing</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jin</LastName>
<ForeName>Hong</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Subbarao</LastName>
<ForeName>Kanta</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>K04 AI000155</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>Z01 AI000155</GrantID>
<Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>ZIA AI000997-06</GrantID>
<Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>05</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Virus Res</MedlineTA>
<NlmUniqueID>8410979</NlmUniqueID>
<ISSNLinking>0168-1702</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adjuvants</Keyword>
<Keyword MajorTopicYN="N">Clinical trials</Keyword>
<Keyword MajorTopicYN="N">H5N1</Keyword>
<Keyword MajorTopicYN="N">Pandemic</Keyword>
<Keyword MajorTopicYN="N">Vaccine strategies</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year>
<Month>10</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2013</Year>
<Month>04</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2013</Year>
<Month>05</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>6</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>6</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>6</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23726847</ArticleId>
<ArticleId IdType="pii">S0168-1702(13)00171-8</ArticleId>
<ArticleId IdType="doi">10.1016/j.virusres.2013.05.006</ArticleId>
<ArticleId IdType="pmc">PMC3795810</ArticleId>
<ArticleId IdType="mid">NIHMS486329</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Vaccine. 2010 Aug 31;28(38):6221-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20638454</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Jun 19;30(29):4341-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22682289</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2004 May 1;172(9):5598-605</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15100303</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2006 Feb 11;367(9509):475-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16473124</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Sep;3(9):e360</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2012 Mar;86(5):2706-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22205751</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Infect Dis J. 2010 Jun;29(6):e35-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20375709</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2000 Feb;74(3):1443-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10627555</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2211-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22308474</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viral Immunol. 2002;15(2):295-323</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12081014</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2007 Jul;5(7):505-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17558426</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1996 Jun;173(6):1467-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8648221</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2004 Aug 13;22(23-24):2993-3003</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15297047</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Immunol. 2004 Jun;16(3):197-203</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15130504</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2008 Nov;82(21):10854-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18715930</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 May 2;26(19):2378-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18407382</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 1995;13(15):1399-402</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8578816</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2012 Jun 21;486(7403):335-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22722191</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 May 22;25(21):4283-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17403562</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2007 Oct;6(5):685-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17931150</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2011 Aug 12;333(6044):850-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21798894</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2007 Aug 18;370(9587):580-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17707753</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2008 Apr 26;371(9622):1427-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18400288</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2006 Jul 27;442(7101):448-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16642006</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2008;3(10):e3462</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18941631</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Nov 25;26(50):6383-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18801398</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2001 Jun 16;357(9272):1937-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11425416</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2008 Oct;8(10):650-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18922487</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Plant Biotechnol J. 2010 Jun;8(5):607-19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20199612</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2013 Jan;7(1):66-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22417012</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2009 Mar 1;199(5):711-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19210163</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2005 Dec 22;353(25):2667-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16371632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(3):e33536</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22470453</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Aug;84(15):7695-702</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20504935</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2012 Feb;18(2):274-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22286307</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2008;3(12):e3942</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19079604</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatrics. 2010 Oct;126(4):e762-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20819892</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2012 Mar;11(3):349-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22380826</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1977 Dec;136 Suppl:S731-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">606798</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2011 Jan 1;52(1):1-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21148512</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Drug Deliv. 2010 Dec;7(12):1433-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21118032</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Avian Dis. 2003;47(3 Suppl):1127-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14575127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2011 Nov;85(21):10945-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21865396</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Dec 9;26(52):6965-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18848593</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Aug 5;26(33):4160-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18599164</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2008 Sep 1;198(5):635-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18694338</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Mar 16;29(13):2461-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21256188</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1995 Jul;172(1):1-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7797897</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Jan;84(1):44-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19864389</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2008 Feb 15;197(4):580-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18237269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 May 10;25(19):3871-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17337102</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2012 Oct 10;432(1):91-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22743127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2005 Oct 20;437(7062):1108</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16228009</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2009 Jun;83(11):5726-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19321609</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2003 Apr;2(2):197-203</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12899571</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2009 Aug;83(16):8131-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19493997</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010;5(12):e15559</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21203523</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Oct 3;26(42):5393-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18706956</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1977 Dec;136 Suppl:S571-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">342629</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1997 Feb;175(2):342-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9203655</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2005 Apr 15;191(8):1210-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15776364</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2013;346:f794</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23444425</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 Apr 3;363(9415):1099-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15064027</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Apr 12;29(17):3144-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21377509</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Apr 21;27(18):2506-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19368793</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dev Biol (Basel). 2003;115:63-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15088777</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Plant Biotechnol J. 2008 Dec;6(9):930-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19076615</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2008;3(1):e1501</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18231588</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2008 Sep 1;198(5):642-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18576945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2011 Dec;11(12):916-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21975270</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 May 4;25(18):3554-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17293015</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2005 Dec 21;294(23):3019-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16414950</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Nov 5;27(47):6512-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19729082</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1978 May 18;273(5659):238-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">306072</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1983 Jul 7;309(1):13-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6602294</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Jun 2;26(23):2930-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18440103</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2009 May 12;106(19):7962-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19416838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Dec 16;29(2):166-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21055500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2009;4(3):e4667</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19252744</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2005 Jan 27;352(4):333-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15668219</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Oct;81(19):10558-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17634234</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 1986 Jan;23(1):66-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3700610</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2008 Jun 15;197(12):1643-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18513153</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wkly Epidemiol Rec. 2008 Oct 3;83(40):359-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18833663</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2009 Oct 1;200(7):1113-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19712040</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2006 Nov 23;355(21):2186-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17124016</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Med Res Methodol. 2010;10:18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20210985</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Feb;79(4):2191-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15681421</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 1981 Nov;34(2):354-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7309229</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Aug 6;27(36):4953-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19540952</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2008 Jun 12;358(24):2573-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18550874</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2010 Feb;6(2):e1000796</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20195520</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wkly Epidemiol Rec. 2009 Oct 9;84(41):432-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19817020</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1999 Apr;73(4):3184-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10074171</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2001 Feb 8;19(13-14):1732-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11166898</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2011;6(6):e20641</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21687736</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2009 Apr;8(4):499-508</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19348565</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2011 Oct;18(10):1710-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21813657</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2007 Oct 25;367(2):275-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17599381</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2006 Sep 16;368(9540):991-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16980114</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2009;4(2):e4384</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19197383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2012 Aug;122(8):2847-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22820287</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2001 Jul;75(13):6154-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11390617</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2002 Aug;8(8):796-801</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12141964</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2009 Apr 10;324(5924):246-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19251591</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Feb;84(3):1237-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19906909</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Mar 16;28(13):2565-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20117262</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Formos Med Assoc. 2012 Jun;111(6):333-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22748624</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2009 Dec 20;395(2):182-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19836045</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(2):e31177</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22363572</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2006 Nov 1;194 Suppl 2:S111-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17163383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Sep;79(18):11788-800</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16140756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Immunol. 2011 Jun;31(3):443-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21174144</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2845-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16473931</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Infect Dis J. 2008 Dec;27(12):1052-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18978514</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Microbiol Immunol. 2009;333:197-210</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19768407</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Jun 19;26(26):3209-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18462843</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2013 Mar;13(3):238-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23369412</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Stand. 1979 Apr;7(2):123-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">479199</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2010 Jan 20;2(15):15ra5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20371470</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2009 Mar;5(3):e1000350</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19300497</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2008 Mar 1;197(5):667-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18260764</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods. 2006 Sep;40(1):60-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16997714</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2005 Nov 16;23(46-47):5404-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16011865</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2006 Jan;12(1):48-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16494717</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 May;84(10):4936-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20200248</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br Med Bull. 1979 Jan;35(1):69-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">367490</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2009 Dec 20;395(2):280-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19833372</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2009 Jan 1;199(1):49-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19032063</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Struct Mol Biol. 2009 Mar;16(3):265-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19234466</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Biotechnol Biochem. 2007 Oct;71(10):2358-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17928717</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2006 May 20;367(9523):1657-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16714186</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2008;3(6):e2517</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18575608</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2008 Jan 17;358(3):261-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18199865</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Biotechnol. 2007 Dec;18(6):537-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18083549</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Cell Biol. 2008 May-Jun;86(4):343-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18362946</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2008 Mar;82(5):2565-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18094159</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2001 Sep 7;293(5536):1840-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11546875</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2007 May;13(5):807-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18044056</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sleep. 2010 Nov;33(11):1428-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21102981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1979 May;95(1):197-207</Citation>
<ArticleIdList><ArticleId IdType="pubmed">442540</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2008;3(12):e4028</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19112513</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2010 Nov;17(11):1817-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20810680</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2009 Aug;15(8):1252-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19751587</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Feb 6;31(8):1246-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23246544</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2002 May;76(9):4420-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11932409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2008 Oct 9;359(15):1631-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18843132</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1990 Sep;64(9):4523-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2117072</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1998 Jan 16;279(5349):393-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9430591</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunology. 1986 Jul;58(3):417-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2426185</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 2005 May;23(5):567-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15877075</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wkly Epidemiol Rec. 2012 Mar 16;87(11):97-108</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22462204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2002 May 15;20 Suppl 2:S66-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12110263</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2003 Apr 2;21(15):1687-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12639491</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1996 Oct;174(4):838-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8843225</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2009 Jan 15;199(2):184-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19067606</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Public Health Nations Health. 1935 Mar;25(3):298-300</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18014174</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1968 Aug 10;219(5154):645-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5665725</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2008;3(2):e1665</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18301743</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1948 Apr;58(4):369-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18864082</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2005 Feb;86(Pt 2):423-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15659762</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacol Ther. 2007 Dec;82(6):665-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17957181</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2008 Nov;2(6):203-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19453396</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin. 2006 Mar-Apr;2(2):74-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17012880</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Med (Berl). 2011 Apr;89(4):331-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21104066</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 1999 Oct 9;354(9186):1277-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10520648</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2006 Mar 30;354(13):1343-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16571878</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2012 Jul;55(1):19-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22441650</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2001 Mar 21;19(17-19):2666-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11257407</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2006 Feb;80(4):1959-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16439551</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2003 Jan 5;305(1):192-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12504552</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2008;3(1):e1401</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18167560</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2009 Apr 15;48(8):1087-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19281330</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2011 Jun 15;203(12):1729-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21606531</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1988 Jan;85(2):324-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2829180</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2009 Apr;16(4):437-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19020111</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2011 Aug 12;333(6044):843-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21737702</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><noCountry><name sortKey="Cheng, Xing" sort="Cheng, Xing" uniqKey="Cheng X" first="Xing" last="Cheng">Xing Cheng</name>
<name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name>
<name sortKey="Luke, Catherine J" sort="Luke, Catherine J" uniqKey="Luke C" first="Catherine J" last="Luke">Catherine J. Luke</name>
<name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
</noCountry>
<country name="États-Unis"><region name="Maryland"><name sortKey="Baz, Mariana" sort="Baz, Mariana" uniqKey="Baz M" first="Mariana" last="Baz">Mariana Baz</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A09 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000A09 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:23726847
   |texte=   H5N1 vaccines in humans.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:23726847" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a PandemieGrippaleV1

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

H5N1 vaccines in humans.

H5N1 vaccines in humans.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki